| You are here: Home: BCU 7|2003: A
CME Audio Series and Activity
Breast Cancer Update: A CME Audio Series and Activity
STATEMENT OF NEED/TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical
oncology. Published results from a plethora of ongoing clinical
trials lead to the continuous emergence of new therapeutic agents
and changes in the indications for existing treatments. In order
to offer optimal patient care - including the option of clinical
trial participation - the practicing medical oncologist must be
well-informed of these advances. To bridge the gap between research
and patient care, Breast Cancer Update uses one-on-one discussions
with leading oncology investigators. By providing access to the
latest research developments and expert perspectives, this CME
program assists medical oncologists in the formulation of up-to-date
clinical management strategies.
GLOBAL LEARNING OBJECTIVES
Upon completion of this activity, participants should be able
to:
- Critically evaluate the clinical implications of emerging clinical
trial data in breast cancer treatment.
- Describe and implement an algorithm for HER2 testing and treatment
of patients with HER2-positive breast cancer.
- Develop and explain a management strategy for treatment of
ER-positive breast cancer in the adjuvant, neoadjuvant and metastatic
settings.
- Develop and explain a management strategy for treatment of
ER-negative breast cancer in the adjuvant, neoadjuvant and metastatic
settings.
- Counsel postmenopausal patients with ER-positive breast cancer
about the risks and benefits of aromatase inhibitors in the adjuvant
setting.
- Evaluate the emerging data on dose-dense chemotherapy and explain
its relevance to patients.
SPECIFIC LEARNING OBJECTIVES FOR ISSUE 7
Upon completion of this activity, participants should be able
to:
- Discuss the efficacy and tolerability of the trastuzumab/taxane/carboplatin
combination, and the ongoing related trials to assist in the
management of select patients with HER2-positive disease in the
metastatic setting.
- Describe the efficacy and tolerability of fulvestrant in order
to counsel patients with ER-positive metastatic disease about
therapy options.
- Evaluate the Women's Health Initiative trial results to counsel
women regarding the beneficial and detrimental effects associated
with menopausal hormone therapy.
- Evaluate novel data regarding dose-dense scheduling of chemotherapy
and the use of taxanes in the adjuvant setting.
- Describe a management strategy for the use of chemotherapy
and endocrine therapy in women with metastatic disease.
ACCREDITATION STATEMENT
NL Communications is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education
for physicians.
CREDIT DESIGNATION STATEMENT
NL Communications designates this educational activity for a maximum
of 3.25 category 1 credits towards the AMA Physician's Recognition
Award. Each physician should claim only those credits that he/she
actually spent on the activity.
|
